Dr. Jack Cush reviews this week's news from RheumNow.com, including: placebo trumps controversial therapies, the dynamics of disease activity, fuse the big toe, and patients don’t appreciate being told “it's all in your head”!
All News
There's this low grade buzz from some rheumatologists about the potential analgesic benefits of low dose naltrexone. I haven't used it. Should you?
In honor of World Arthritis Day (Oct. 12th), The Lancet has published a public Health Policy report is to "outline a globally relevant roadmap to address the osteoarthritis identity problem, focusing on health policy responses."
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Gabapentin Use Rose as Restrictions Fell, Study Shows
Gabapentin use jumped quickly in Michigan after the drug was removed from the state's controlled substance schedule in 2024, a cross-sectional study showed.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
The American College of Rheumatology (ACR) has released updated clinical guidance for the treatment and management of osteoarthritis (OA) of the knee, hip, and hand. The evidence-based recommendations update the 2019 ACR/Arthritis Foundation guideline and are designed to support individualized, shared decision-making between patients and clinicians.
Even before the introduction of incretin therapy and bariatric surgery, many randomized and interventional studies (2019–2026) have consistently showed that weight loss produces clinically meaningful, dose-dependent improvement in both psoriasis and psoriatic arthritis.
